Navigation Links
Indevus Pharmaceuticals Announces Release of 2008 Annual Report
Date:1/27/2009

LEXINGTON, Mass., Jan. 27 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that a copy of its 2008 Annual Report has been posted on and is available at the Company's website at www.indevus.com. In addition, the Company's stockholders may obtain a free hard copy of the Annual Report by contacting the Company's Investor Relations department at (781) 861-8444 or by mailing written requests to Indevus Pharmaceuticals, Inc., Attention Investor Relations, 33 Hayden Ave., Lexington, Massachusetts 02421.

The Company's common stock is listed and traded on the NASDAQ Global Market under the symbol "IDEV."

About Indevus Pharmaceuticals

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering.

    Contact:
    Michael W. Rogers
    EVP and Chief Financial Officer
    (781) 861-8444

    Robin L. DeCarlo
    Sr. Director, Corporate Communications
    (781) 402-3405


'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
2. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
3. Indevus and FDA Agree on Path Forward for NEBIDO(R)
4. Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
5. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
6. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
7. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
8. Indevus Announces Management Changes
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
11. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... accelerator dedicated to nourishing a range of emerging technology-based businesses, recently earned a ... Metropolitan Court location. , Founded in 2004, FITCI is Frederick’s first incubator. ...
(Date:4/20/2017)... ... April 20, 2017 , ... Husson University will be celebrating ... body of knowledge during its Eighth Annual Research and Scholarship Day ... Atrium. During the event, undergraduates, graduate students, and faculty members from all of ...
(Date:4/20/2017)... ... April 20, 2017 , ... Open ... intellectual property (IP) sharing and commercialization model. , The Center for Advancing Innovation ... component of this effort is bringing the IP to the attention of the ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments ... which is part of the Protein and Cell Analysis Education Webinar Series , ... this technology fits in current and future applications. , Many flow cytometers have ...
Breaking Biology Technology:
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
Breaking Biology News(10 mins):